Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

NCT01659021 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

261

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Idelalisib
DRUG: Ofatumumab

Sponsor

Gilead Sciences